Proteasome Inhibitors Market: Current Analysis and Forecast (2023-2030)

Report Description

The proteasome inhibitor market was valued at USD 1.78 Billion in 2022 and is expected to grow at a CAGR of 8.01% during the forecast period (2023-2030). Proteasome inhibitors are a class of drugs used in cancer treatment, particularly for certain types of blood cancers like multiple myeloma and mantle cell lymphoma. These inhibitors interfere with the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, these drugs disrupt the normal protein degradation process in cancer cells, leading to their accumulation and eventually triggering cell death. Proteasome inhibitors mainly gained prominence in the market due to the rising number of pancreatic cancer cases. For instance, according to the National Cancer Institute, the rate of new cases of pancreatic cancer was 13.3 per 100,000 men and women per year in the year 2020. In addition to this, investments in oncology departments as well as government awareness programs regarding pancreatic cancer have increased significantly in recent years, which are the key factors that are creating opportunities for the market.

AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; Takeda Pharmaceutical Company Limited; TG Therapeutics; Pfizer Inc.; QLi5 Therapeutics GmbH; Baxter; GSK plc.; Kezar Life Sciences Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst mode of administration, intravenous category to witness higher CAGR during the forecast period”

Based on the mode of administration, the market is segmented into oral, intravenous, and others. The intravenous segment is expected to grow with a high CAGR during the forecast period because of its faster mode of action and effectiveness. For instance, according to the National Library of Medicine’s article in February 2023, the intravenous mode of drug administration provides the most complete drug availability with negligible delay. Also, this mode is comfortable for patients who face difficulty in ingesting medicines orally. Thus, the intravenous segment among modes of administration is expected to witness a higher CAGR during the forecast period.

“Amongst indication, held a significant share in the market in 2022”

Based on indication, the market is categorized into mantle cell lymphoma, multiple myeloma, and others. The multiple myeloma segment is dominating the market owing to the rising incidences of multiple myeloma. For instance, according to the American Cancer Society, in the U.S. the average lifetime risk of getting multiple myeloma is about 1 in 103 for men and about 1 in 131 for women. Multiple myeloma is a type of cancer that affects plasma cells, a type of white blood cell in the bone marrow. It often leads to the production of abnormal antibodies and can cause bone damage, anemia, and kidney problems. Thus, multiple myeloma held a significant share in the proteasome inhibitors market in 2022.

“Amongst regions, APAC is expected to witness a higher CAGR during the forecast period”

APAC is expected to grow with a high CAGR in the global proteasome inhibitor market in the forecast period. Several factors such as a surge in the development of a wide range of proteasome inhibitors, enhanced accessibility, and diversified healthcare costs are driving the market’s growth during the forecast period. Further, the increase in incidences of pancreatic cancer is also having a positive impact on the market’s growth. For instance, according to the Indian Journal of Medical Sciences in May 2021, in India, pancreatic cancer ranked 24th with 10860 new cases (1.03%). There have been major awareness programs regarding cancer in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:

The global proteasome inhibitors market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

Get in touch with team

Frequently Asked Questions (FAQ)

Research Methodology

Research Methodology for the Proteasome Inhibitors Market Analysis (2023-2030)

Analyzing the historical market, estimating the current market, and forecasting the future market of the global proteasome inhibitors market were the three major steps undertaken to create and analyze the adoption of proteasome inhibitors in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global proteasome inhibitors market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detail secondary study was conducted to obtain the historical market size of the proteasome inhibitor market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the proteasome inhibitors market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as mode of administration, application, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the proteasome inhibitors market. Further, we conducted factor analysis using dependent and independent variables such as mode of administration, application, and regions of proteasome inhibitors. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the proteasome inhibitors market sector across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global proteasome inhibitors market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 00for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

• The industry’s market size, in terms of revenue (USD) and the adoption rate of the proteasome inhibitors market across the major markets domestically
• All percentage shares, splits, and breakdowns of market segments and sub-segments
• Key players in the global proteasome inhibitors market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Market Engineering

The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global proteasome inhibitor market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of mode of administration, application, and regions in the global proteasome inhibitors market.

The main objective of the Global Proteasome Inhibitor Market Study

The current & future market trends of the global proteasome inhibitors market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:

• Analyze the current and forecast market size of the proteasome inhibitors market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
• Segments in the study include areas of mode of administration, application, and regions
• Define and analyze the regulatory framework for the proteasome inhibitor industry.
• Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
• Analyze the current and forecast market size of the proteasome inhibitors market for the major region.
• Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World.
• Company profiles of the proteasome inhibitors market and the growth strategies adopted by the market players to sustain in the fast-growing market
• Deep dive regional level analysis of the industry

You can also purchase parts of this report. Do you want to check out a section wise
price list?

Get in touch with team